Beacon Biotechnology was founded by a team of brilliant scientists and savvy business professionals with decades of experience in bioscience, medical, academic and commercial settings.

Fred Mitchell has extensive commercial experience in human and veterinary diagnostics. He managed a hospital chemistry laboratory then moved to Bayer Diagnostics where he spent 14 years in progressive roles in sales, marketing and product management. Next, Mr. Mitchell was Director of Business Development for Colorado MEDtech, a leading Boulder, CO medical device engineering firm. Later, he managed the diagnostic instrumentation and vital signs monitoring products at the nation’s 3rd largest companion animal veterinary diagnostics company. Prior to joining Beacon, he managed BioStar’s enteric  rapid test product line for Inverness Medical, the world’s largest rapid diagnostic company. As Chief Executive Officer, Fred is spearheading the commercialization of BrightSPOT™.

Millard Cull is a co-founder and Chief Technology Officer of Beacon Biotechnology, and has over 15 years of experience in the biotechnology industry. In addition, Mr. Cull is CEO of Avidity, LLC, a technology company he co-founded in 1996. He has a BS in Molecular, Cellular and Developmental Biology from University of Colorado, Boulder, and an MBA in Finance from the University of Denver. Millard holds several patents in the field of Directed Molecular Evolution and a patent for the Replicative DNA Polymerase from Thermus thermophylus. He co-authored a paper describing the first use of intercalating dyes in a DNA polymerase assay that served as a forerunner of quantitative PCR (qPCR). Finally, he is the lead inventor on several recently submitted patent applications including the Chemiluminescent Nucleic Acid Proximity Assay (NAPA™).

Larry Lansing is a co-founder of Beacon Biotechnology, and together with Mr. Cull, founded Avidity, LLC in 1996. He serves as CFO of both Beacon and Avidity. He has over 25 years of accounting experience, initially as a Certified Public Accountant (CPA) with a focus on taxation and business consulting. Over the past ten years he has been instrumental in negotiating license agreements for use of Avidity’s patented AviTag™ technology with nine of ten of the world's largest pharmaceutical companies.

Chief Science Officer Dr. Ronald Gill has more than 25 years of biomedical research experience in both biotechnology and academic environments. He earned his PhD in Microbiology from the University of Washington and did post-doctoral work in Biochemistry at Stanford University. His background helps determine the scientific direction of the company. Dr. Gill is a Professor in the University of Colorado Denver School of Medicine and a Member and Senior Scientist with Avidity LLC.

Dr. Eaton is a Professor and the Chairman of the Department of Chemistry and Biochemistry  at CU Boulder and a member of the Colorado Initiative in Molecular Biotechnology Task Force (Ph.D. UC Berkeley, NIH Distinguished Lecture 2008, Sr. Scientific Advisor - SomaLogic 2003-present). He has served in a variety of executive roles since 1992 in the biotechnology and pharmaceutical industry leading to new technologies and commercial products. Current research interests funded in his research group include RNA catalysis, high resolution cellular imaging, nanotechnology applications in biology and evolution of light harvesting systems for photochemical water splitting.

Dr. Cambier is the Ida and Cecil Green Professor and Chairman of the Department of Immunology at the University of Colorado Denver School of Medicine and National Jewish Health. He is cited on 52 papers and has authored or co-authored 5 books related to immunology. He is an accomplished, frequently invited guest speaker and has participated in numerous professional boards and committees and on the editorial board of several professional publications including the Journal of Clinical Immunology (2003–2007) and Immunological Reviews (2002–2007).